Related Experiment Video

Updated: Jul 7, 2026

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest
04:55

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest

Published on: May 26, 2023

Pediatric myocardial protection

Yves Durandy1

  • 1Institut Hospitalier Jacques Cartier, Massy, France. iciprea@icip.org

Current Opinion in Cardiology
|February 28, 2008
PubMed

Insights

Pediatric cardiac surgery is advancing with new myocardial protection strategies. Warm perfusion and blood cardioplegia show promise over traditional hypothermic methods, improving outcomes in heart surgery.

Area of Science:

  • Pediatric Cardiac Surgery
  • Cardiovascular Research
  • Myocardial Protection

Background:

  • Myocardial protection is crucial for pediatric cardiac surgery advancements.
  • Current research evaluates new perfusion techniques and cardioplegia.
  • Genetic factors are emerging as tools for assessing and enhancing myocardial protection.

Purpose of the Study:

  • To review current advancements in myocardial protection for pediatric cardiac surgery.
  • To evaluate the efficacy of novel perfusion techniques and cardioplegia strategies.
  • To explore the role of genetic factors in myocardial protection.

Main Methods:

  • Review of recent literature on pediatric cardiac surgery and myocardial protection.
  • Analysis of studies comparing hypothermic versus warm perfusion techniques.
  • Evaluation of evidence supporting blood cardioplegia over crystalloid cardioplegia.
  • Assessment of heat shock protein upregulation in myocardial protection.

Main Results:

  • Increasing doubt exists regarding the efficacy of hypothermia in preventing postoperative complications.
  • Pediatric perfusion is shifting towards warm perfusion to mitigate hypothermia's side effects.
  • Blood cardioplegia demonstrates superiority over crystalloid cardioplegia.
  • Intermittent warm blood cardioplegia has shown efficiency and safety in European studies.
  • Small bypass circuits and blood-free surgery are under validation.

Conclusions:

  • Cardioplegia is paramount for myocardial protection in pediatric cardiac surgery.
  • Emerging evidence supports warm surgery with low prime bypass and intermittent warm blood cardioplegia.
  • This approach offers a valid alternative to traditional hypothermic perfusion with cold cardioplegia.
Abstract

More Related Videos

A Microscopic 2,3,5-Triphenyltetrazolium Chloride Assay for Accurate and Reliable Analysis of Myocardial Injury11:17

A Microscopic 2,3,5-Triphenyltetrazolium Chloride Assay for Accurate and Reliable Analysis of Myocardial Injury

Published on: November 28, 2025

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...